Octreotide Arrow (Octreotide Acetate)

Octreotide acetate, the active ingredient in Octreotide Arrow, is a peptide presented as a formulation for injectable use. It modulates hormone secretion and is employed in the management of certain endocrine‑related disorders in adults.

GNH USA supplies Octreotide Arrow as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty pharmacies worldwide.

Octreotide Arrow is a synthetic analogue of somatostatin that acts on neuroendocrine pathways. It is indicated for: - Acromegaly: reduces growth hormone and IGF‑1 levels, helping control disease activity. - Carcinoid syndrome: lessens flushing and diarrhoea by inhibiting serotonin release. - VIPoma/Medullary thyroid carcinoma associated diarrhea: controls severe secretory diarrhoea. - Preventive control of postoperative pancreatic fistula after major pancreatic surgery, where evidence supports its use. - Management of hypoglycaemia related to insulinoma or nesidioblastosis by suppress of insulin secretion. - Control of bleeding from varice various gastro‑intestinal bleeds where som­ som pathways are involved.

Octreotide Arrow may cause a range of adverse reactions.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal cramping or diarrhoea. - Injection‑site reactions: erythema, pain or induration. - Gallbladder changes: biliary sludge or gallstones. - Metabolic alterations: hyperglycaemia or hypoglycaemia. - Headache or fatigue.

Serious or Rare Side Effects: - Pancreatitis. - Severe hypersensitivity reactions, including anaphylaxis. - Cardiac arrhythmias. - Acute cholecystitis. - Significant electrolyte disturbances.

Octreotide Arrow should be used with clinical oversight and consideration of patient‑specific factors.

- Renal impairment: dose adjustment may be required. - Hepatic dysfunction: monitor liver enzymes and gallbladder status. - Diabetes mellitus: monitor blood glucose closely, as the drug can affect glycaemic control. - Cardiovascular disease: observe for brady‑cardia or arrhythmias. - Pregnancy and lactation: only use if the potential benefit outweighs risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octreotide Arrow can influence the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Cytochrome P450 substrates metabolised by CYP3A4 (e.g., midazolam) – may have reduced exposure. - Long‑acting octreotide formulations – risk of additive hormonal suppression.

Moderate Interactions (Monitor Closely): - Insulin or oral hypoglycaemic agents – risk of hypoglycaemia or hyperglycaemia. - Antiplatelet or anticoagulant drugs – potential for altered bleeding risk. - Thyroid hormone replacement – may require dose adjustment.